Navigating drug discovery in complex environments with Pelago Bioscience
27 Nov 2024
Understanding biological processes is crucial in complex environments, therefore having wider knowledge of the physiological environment improves success in drug discovery, which is often uncertain. Explore CETSA® from Pelago Bioscience, the sophisticated technology used to assess cellular protein-ligand binding. Unlike other target engagement methods, CETSA allows assessment and quantification in cellular environments under actual physiological conditions – without the need to modify the compound or protein.
About the company
Pelago Bioscience
Pelago Bioscience was founded in 2013 with the aim to develop the patented Cellular Thermal Shift Assay (CETSA®) for maximum utility and customer value in drug discovery and diagnostics. Today, Pelago Bioscience is a Drug Discovery Research Partner supporting preclinical drug discovery and development. Pelago offer a range of services, from confirming target engagement to strengthening target validation and understanding the mechanism of action of your compounds. The approach is designed to help you make better decisions faster.
Related products
Request Quote for All Products
Primary Screening with CETSA
Pelago BiosciencePrimary screening based on Cellular Thermal Shift Assay (CETSA) allows for rapid identification of high quality chemical starting points against the native, full-length protein in live cells.
Hit confirmation with CETSA
Pelago BioscienceHit confirmation service is based on the Cellular Thermal Shift Assay (CETSA) and allows for assessment of compound binding to a selected target protein in its native state without any modifications to the protein or the compound.
Target Deconvolution with CETSA
Pelago BioscienceTarget Deconvolution service based on proteome-wide Cellular Thermal Shift Assay using Mass Spectrometry detection is performed in intact cells and lysate without any compound modifications.
